Genmab A/S Logo

Genmab A/S

GMAB

(2.5)
Stock Price

20,31 USD

22.84% ROA

14.61% ROE

18.77x PER

Market Cap.

101.782.550.312,38 USD

3.29% DER

0% Yield

23.47% NPM

Genmab A/S Stock Analysis

Genmab A/S Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Genmab A/S Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (17.26%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (3%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

5 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (1.076), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 PBV

The stock's elevated P/BV ratio (5.08x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

Genmab A/S Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Genmab A/S Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Genmab A/S Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Genmab A/S Revenue
Year Revenue Growth
2002 0
2003 68.326.000 100%
2004 4.101.000 -1566.08%
2005 98.505.000 95.84%
2006 135.547.000 27.33%
2007 529.537.000 74.4%
2008 745.113.000 28.93%
2009 586.076.000 -27.14%
2010 582.077.000 -0.69%
2011 350.936.000 -65.86%
2012 484.636.000 27.59%
2013 663.570.000 26.97%
2014 850.385.000 21.97%
2015 1.133.041.000 24.95%
2016 1.816.122.000 37.61%
2017 2.365.436.000 23.22%
2018 3.025.137.000 21.81%
2019 5.366.000.000 43.62%
2020 10.111.000.000 46.93%
2021 8.482.000.000 -19.21%
2022 14.595.000.000 41.88%
2023 18.976.000.000 23.09%
2023 16.474.000.000 -15.19%
2024 21.608.000.000 23.76%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Genmab A/S Research and Development Expenses
Year Research and Development Expenses Growth
2002 396.234.000
2003 345.983.000 -14.52%
2004 373.330.000 7.33%
2005 304.103.000 -22.76%
2006 359.953.000 15.52%
2007 618.503.000 41.8%
2008 1.422.770.000 56.53%
2009 935.361.000 -52.11%
2010 0 0%
2011 0 0%
2012 536.702.000 100%
2013 527.576.000 -1.73%
2014 505.679.000 -4.33%
2015 487.656.000 -3.7%
2016 660.876.000 26.21%
2017 874.278.000 24.41%
2018 1.431.159.000 38.91%
2019 2.386.000.000 40.02%
2020 3.137.000.000 23.94%
2021 4.181.000.000 24.97%
2022 5.562.000.000 24.83%
2023 8.352.000.000 33.41%
2023 7.435.000.000 -12.33%
2024 10.008.000.000 25.71%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Genmab A/S General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 86.847.000
2003 64.552.000 -34.54%
2004 72.044.000 10.4%
2005 38.040.000 -89.39%
2006 37.113.000 -2.5%
2007 38.593.000 3.83%
2008 143.529.000 73.11%
2009 148.749.000 3.51%
2010 160.254.000 7.18%
2011 67.851.000 -136.19%
2012 64.613.000 -5.01%
2013 66.741.000 3.19%
2014 79.529.000 16.08%
2015 91.224.000 12.82%
2016 102.413.000 10.93%
2017 146.987.000 30.33%
2018 213.695.000 31.22%
2019 342.000.000 37.52%
2020 661.000.000 48.26%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Genmab A/S EBITDA
Year EBITDA Growth
2002 669.752.000
2003 -179.803.000 472.49%
2004 -292.968.000 38.63%
2005 -360.462.000 18.72%
2006 -419.703.000 14.11%
2007 -367.967.000 -14.06%
2008 -879.414.000 58.16%
2009 -896.014.000 1.85%
2010 -239.901.000 -273.49%
2011 -532.313.000 54.93%
2012 -471.918.000 -12.8%
2013 122.599.000 484.93%
2014 313.731.000 60.92%
2015 789.467.000 60.26%
2016 1.171.386.000 32.6%
2017 1.136.273.000 -3.09%
2018 1.699.985.000 33.16%
2019 2.897.000.000 41.32%
2020 6.756.000.000 57.12%
2021 3.463.000.000 -95.09%
2022 7.043.000.000 50.83%
2023 7.840.000.000 10.17%
2023 5.648.000.000 -38.81%
2024 8.432.000.000 33.02%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Genmab A/S Gross Profit
Year Gross Profit Growth
2002 0
2003 68.326.000 100%
2004 4.101.000 -1566.08%
2005 98.505.000 95.84%
2006 135.547.000 27.33%
2007 529.537.000 74.4%
2008 696.301.000 23.95%
2009 586.076.000 -18.81%
2010 -435.000 134830.11%
2011 -181.571.000 99.76%
2012 484.636.000 137.47%
2013 663.570.000 26.97%
2014 850.385.000 21.97%
2015 1.133.041.000 24.95%
2016 1.816.122.000 37.61%
2017 2.365.436.000 23.22%
2018 3.025.137.000 21.81%
2019 5.366.000.000 43.62%
2020 10.111.000.000 46.93%
2021 8.482.000.000 -19.21%
2022 14.595.000.000 41.88%
2023 18.576.000.000 21.43%
2023 15.921.000.000 -16.68%
2024 20.848.000.000 23.63%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Genmab A/S Net Profit
Year Net Profit Growth
2002 -479.329.000
2003 -327.114.000 -46.53%
2004 -415.212.000 21.22%
2005 -393.590.000 -5.49%
2006 -438.236.000 10.19%
2007 -383.369.000 -14.31%
2008 -965.089.000 60.28%
2009 -1.010.760.000 4.52%
2010 -321.456.000 -214.43%
2011 -596.368.000 46.1%
2012 -487.118.000 -22.43%
2013 112.362.000 533.53%
2014 301.296.000 62.71%
2015 763.513.000 60.54%
2016 1.187.075.000 35.68%
2017 1.103.551.000 -7.57%
2018 1.472.141.000 25.04%
2019 2.166.000.000 32.03%
2020 4.758.000.000 54.48%
2021 2.957.000.000 -60.91%
2022 5.452.000.000 45.76%
2023 8.516.000.000 35.98%
2023 4.352.000.000 -95.68%
2024 5.632.000.000 22.73%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Genmab A/S Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -2
2003 -1 -100%
2004 -2 0%
2005 -1 0%
2006 -1 0%
2007 -1 0%
2008 -2 100%
2009 -2 0%
2010 -1 0%
2011 -1 100%
2012 -1 0%
2013 0 0%
2014 1 0%
2015 1 100%
2016 2 0%
2017 2 0%
2018 2 50%
2019 3 33.33%
2020 7 57.14%
2021 5 -75%
2022 8 50%
2023 13 38.46%
2023 7 -116.67%
2024 9 25%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Genmab A/S Free Cashflow
Year Free Cashflow Growth
2002 -409.137.000
2003 -317.066.000 -29.04%
2004 -375.964.000 15.67%
2005 -211.078.000 -78.12%
2006 -381.562.000 44.68%
2007 493.056.000 177.39%
2008 -566.349.000 187.06%
2009 -586.839.000 3.49%
2010 258.061.000 327.4%
2011 -444.430.000 158.07%
2012 61.921.000 817.74%
2013 -138.364.000 144.75%
2014 57.229.000 341.77%
2015 176.060.000 67.49%
2016 294.610.000 40.24%
2017 1.500.462.000 80.37%
2018 537.420.000 -179.2%
2019 1.215.000.000 55.77%
2020 6.126.000.000 80.17%
2021 1.976.000.000 -210.02%
2022 3.595.000.000 45.03%
2023 1.939.000.000 -85.4%
2023 7.004.000.000 72.32%
2024 1.486.000.000 -371.33%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Genmab A/S Operating Cashflow
Year Operating Cashflow Growth
2002 -308.316.000
2003 -302.364.000 -1.97%
2004 -367.698.000 17.77%
2005 -208.644.000 -76.23%
2006 -379.623.000 45.04%
2007 505.898.000 175.04%
2008 -513.333.000 198.55%
2009 -570.061.000 9.95%
2010 268.171.000 312.57%
2011 -437.225.000 161.33%
2012 70.919.000 716.51%
2013 -127.999.000 155.41%
2014 132.671.000 196.48%
2015 311.449.000 57.4%
2016 327.719.000 4.96%
2017 1.588.972.000 79.38%
2018 1.014.786.000 -56.58%
2019 1.326.000.000 23.47%
2020 6.433.000.000 79.39%
2021 2.228.000.000 -188.73%
2022 3.912.000.000 43.05%
2023 2.037.000.000 -92.05%
2023 7.380.000.000 72.4%
2024 1.513.000.000 -387.77%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Genmab A/S Capital Expenditure
Year Capital Expenditure Growth
2002 100.821.000
2003 14.702.000 -585.76%
2004 8.266.000 -77.86%
2005 2.434.000 -239.61%
2006 1.939.000 -25.53%
2007 12.842.000 84.9%
2008 53.016.000 75.78%
2009 16.778.000 -215.99%
2010 10.110.000 -65.95%
2011 7.205.000 -40.32%
2012 8.998.000 19.93%
2013 10.365.000 13.19%
2014 75.442.000 86.26%
2015 135.389.000 44.28%
2016 33.109.000 -308.92%
2017 88.510.000 62.59%
2018 477.366.000 81.46%
2019 111.000.000 -330.06%
2020 307.000.000 63.84%
2021 252.000.000 -21.83%
2022 317.000.000 20.5%
2023 98.000.000 -223.47%
2023 376.000.000 73.94%
2024 27.000.000 -1292.59%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Genmab A/S Equity
Year Equity Growth
2002 1.399.169.000
2003 1.086.434.000 -28.79%
2004 1.180.986.000 8.01%
2005 1.118.770.000 -5.56%
2006 1.607.582.000 30.41%
2007 2.883.279.000 44.24%
2008 2.188.562.000 -31.74%
2009 1.297.192.000 -68.72%
2010 1.080.067.000 -20.1%
2011 486.418.000 -122.05%
2012 383.187.000 -26.94%
2013 659.523.000 41.9%
2014 2.032.939.000 67.56%
2015 3.486.720.000 41.69%
2016 4.826.696.000 27.76%
2017 6.272.192.000 23.05%
2018 8.014.360.000 21.74%
2019 14.048.000.000 42.95%
2020 19.121.000.000 26.53%
2021 22.196.000.000 13.85%
2022 27.441.000.000 19.11%
2023 31.112.000.000 11.8%
2023 31.610.000.000 1.58%
2024 30.969.000.000 -2.07%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Genmab A/S Assets
Year Assets Growth
2002 1.583.136.000
2003 1.180.108.000 -34.15%
2004 1.271.908.000 7.22%
2005 1.370.431.000 7.19%
2006 1.804.629.000 24.06%
2007 3.958.783.000 54.41%
2008 3.258.953.000 -21.47%
2009 2.221.534.000 -46.7%
2010 2.481.601.000 10.48%
2011 1.564.432.000 -58.63%
2012 1.692.886.000 7.59%
2013 1.731.527.000 2.23%
2014 2.866.681.000 39.6%
2015 3.902.548.000 26.54%
2016 5.238.236.000 25.5%
2017 6.602.942.000 20.67%
2018 8.460.999.000 21.96%
2019 15.144.000.000 44.13%
2020 21.143.000.000 28.37%
2021 24.627.000.000 14.15%
2022 30.278.000.000 18.66%
2023 35.238.000.000 14.08%
2023 35.289.000.000 0.14%
2024 38.619.000.000 8.62%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Genmab A/S Liabilities
Year Liabilities Growth
2002 183.967.000
2003 93.674.000 -96.39%
2004 90.922.000 -3.03%
2005 251.661.000 63.87%
2006 197.047.000 -27.72%
2007 1.075.504.000 81.68%
2008 1.070.391.000 -0.48%
2009 924.342.000 -15.8%
2010 1.401.534.000 34.05%
2011 1.078.014.000 -30.01%
2012 1.309.699.000 17.69%
2013 1.072.004.000 -22.17%
2014 833.742.000 -28.58%
2015 415.828.000 -100.5%
2016 411.540.000 -1.04%
2017 330.750.000 -24.43%
2018 446.639.000 25.95%
2019 1.096.000.000 59.25%
2020 2.022.000.000 45.8%
2021 2.431.000.000 16.82%
2022 2.837.000.000 14.31%
2023 4.126.000.000 31.24%
2023 3.679.000.000 -12.15%
2024 7.650.000.000 51.91%

Genmab A/S Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
29.43
Net Income per Share
8.54
Price to Earning Ratio
18.77x
Price To Sales Ratio
5.37x
POCF Ratio
15.33
PFCF Ratio
15.62
Price to Book Ratio
3.33
EV to Sales
5.19
EV Over EBITDA
13.81
EV to Operating CashFlow
14.62
EV to FreeCashFlow
15.11
Earnings Yield
0.05
FreeCashFlow Yield
0.06
Market Cap
101,78 Bil.
Enterprise Value
98,47 Bil.
Graham Number
96.09
Graham NetNet
19.75

Income Statement Metrics

Net Income per Share
8.54
Income Quality
1.11
ROE
0.17
Return On Assets
0.12
Return On Capital Employed
0.18
Net Income per EBT
0.72
EBT Per Ebit
1.04
Ebit per Revenue
0.31
Effective Tax Rate
0.28

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.47
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.96
Operating Profit Margin
0.31
Pretax Profit Margin
0.33
Net Profit Margin
0.23

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
10.45
Free CashFlow per Share
10.11
Capex to Operating CashFlow
0.03
Capex to Revenue
0.01
Capex to Depreciation
0.58
Return on Invested Capital
0.14
Return on Tangible Assets
0.23
Days Sales Outstanding
118.7
Days Payables Outstanding
2064.89
Days of Inventory on Hand
21.86
Receivables Turnover
3.08
Payables Turnover
0.18
Inventory Turnover
16.69
Capex per Share
0.34

Balance Sheet

Cash per Share
24,42
Book Value per Share
48,06
Tangible Book Value per Share
25.51
Shareholders Equity per Share
48.06
Interest Debt per Share
1.64
Debt to Equity
0.03
Debt to Assets
0.03
Net Debt to EBITDA
-0.46
Current Ratio
5.03
Tangible Asset Value
16,44 Bil.
Net Current Asset Value
14,29 Bil.
Invested Capital
33982000000
Working Capital
17,57 Bil.
Intangibles to Total Assets
0.38
Average Receivables
5,42 Bil.
Average Payables
2,96 Bil.
Average Inventory
71000000
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Genmab A/S Dividends
Year Dividends Growth

Genmab A/S Profile

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

CEO
Dr. Jan G.J. van de Winkel Ph.
Employee
2.635
Address
Kalvebod Brygge 43
Copenhagen, 1560

Genmab A/S Executives & BODs

Genmab A/S Executives & BODs
# Name Age
1 Mr. Martin Schultz
Senior Director of Clinical Operations & Non-Independent Director
70
2 Dr. Judith V. Klimovsky M.D.
Executive Vice President & Chief Development Officer
70
3 Dr. Martine J. van Vugt Ph.D.
Executive Vice President & Chief Strategy Officer
70
4 Dr. Mijke Zachariasse Ph.D.
Senior Director, Head of Antibody Research Materials & Non-Independent Director
70
5 Mr. Christopher Cozic
Executive Vice President & Chief People Officer
70
6 Dr. Jan G.J. van de Winkel Ph.D.
Co-Founder, President & Chief Executive Officer
70
7 Mr. Anthony Pagano CPA
Executive Vice President & Chief Financial Officer
70
8 Ms. Birgitte Stephensen M.Sc.
Executive Vice President & Chief Legal Officer
70
9 Dr. Tahamtan Ahmadi
Executive Vice President, Chief Medical Officer & Head of Experimental Medicines
70
10 Mr. Takahiro Hamatani
Senior Director of Finance Japan & Non-Independent Director
70

Genmab A/S Competitors